Back to results
US 2019/0169610 A1Published application
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
AssigneeIonis Pharmaceuticals, Inc.
InventorsSusan M. Freier, Eric E. Swayze
Life of this patent
Estimating the term…
Abstract
The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
Claims21
-238. (canceled)
A compound comprising:
- a modified oligonucleotide consisting of 10 to 20 linked nucleosides, wherein the modified oligonucleotide comprises:
- a 5′-wing consisting of 2 to 5 linked nucleosides;
- a 3′-wing consisting of 2 to 5 linked nucleosides;
- and
- a gap between the 5′-wing and the 3′-wing consisting of 6 to 14 linked 2′-deoxynucleosides;
- and
- wherein at least one of the 5′-wing and the 3′-wing comprises at least one bicyclic nucleoside selected from among LNA, α-L-LNA, or ENA;
- at least one of the 5′-wing and the 3′-wing comprises at least one 2′-substituted nucleoside;
- and at least one of the 5′-wing and the 3′-wing comprises at least one 2′-deoxynucleoside;
- and
- wherein the nucleobase sequence of the modified oligonucleotide is complementary to the nucleobase sequence of a target nucleic acid.
8 more elements
Dependencies are inferred from the claim text.